Physician profile
Andrew Spinak
NPI 1558364505
$4,917.83
in general payments reported to CMS, 2019-2025
24 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $225 · 2021: $299 · 2022: $338 · 2023: $830 · 2024: $1,270 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,508.22 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,397.82 | 2019-2025 | Idosetr, Istent, Istent Infinite |
| Alcon Vision LLC | $796.65 | 2019-2025 | Rocklatan, Tryptyr, Rhopressa |
| Sun Pharmaceutical Industries INC. | $672.06 | 2019-2025 | Cequa |
| Rxsight INC | $439.50 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $392.57 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $216.95 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Allergan, INC. | $145.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $130.45 | 2019-2023 | |
| Oyster Point Pharma, INC. | $84.63 | 2024-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $74.86 | 2023-2025 | Dextenza |
| Sight Sciences, INC. | $72.06 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $67.52 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $66.02 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.52 | 2019-2021 | |
| Harrow Eye, LLC | $54.95 | 2025 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $45.10 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $41.15 | 2019-2021 | |
| Biotissue Holdings INC. | $34.31 | 2021-2022 | |
| Dompe US, INC. | $32.75 | 2021 | |
| Kala Pharmaceuticals, INC. | $24.87 | 2019 | |
| Shire North American Group INC | $22.61 | 2019 | |
| Rayner Intraocular Lenses Limited | $18.79 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.80 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Spinak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.